medical_xpress
@zpcbeqyqyryncom
Gantenerumab trial for dominantly inherited Alzheimer's halted due to safety concerns. Despite reducing #AmyloidPlaques, the #Treatment showed no significant cognitive benefits and posed serious risks. @TheLancet https://t.co/KSuXtduE8C https://t.co/0CtigTzYmw
0 reply
0 recast
0 reaction